Diffuse Intrinsic Pontine Glioma Clinical Trial
Official title:
An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES: I. To determine the safety and tolerability of repeated administration of MTX110 co-infused with gadoteridol given by intratumoral convection enhanced delivery in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). SECONDARY OBJECTIVES: I. To determine the clinical efficacy of repeated administration of MTX110 given by intratumoral convection-enhanced delivery (CED) in children with newly diagnosed DIPG in the confines of a phase I and early efficacy study. OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Participants receive panobinostat nanoparticle formulation MTX110 intratumorally (IT) by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment participants are followed up at 30 days and then every 2 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Recruiting |
NCT05476939 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
|
Phase 3 | |
Terminated |
NCT03330197 -
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
|
Phase 1/Phase 2 | |
Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02992015 -
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
|
Early Phase 1 | |
Terminated |
NCT01182350 -
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
|
Phase 2 | |
Recruiting |
NCT04837547 -
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04911621 -
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
Active, not recruiting |
NCT02420613 -
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
|
Phase 1 | |
Completed |
NCT03086616 -
CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)
|
Phase 1 | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
Withdrawn |
NCT03632317 -
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
|
Phase 2 | |
Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
Recruiting |
NCT02233049 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
|
Phase 2 | |
Completed |
NCT00996723 -
Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
|
Phase 1 | |
Recruiting |
NCT05009992 -
Combination Therapy for the Treatment of Diffuse Midline Gliomas
|
Phase 2 | |
Recruiting |
NCT04049669 -
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
|
Phase 2 |